LivingGLP1
Study S002564

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

ClinicalTrials.gov record

Registration

Registration
NCT03363464
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
230000
Start
2017-10-16
Primary completion
2026-07-09
Lead sponsor
Boehringer Ingelheim
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:Empagliflozin; DRUG:DPP-4 inhibitor; DRUG:GLP-1 receptor agonist
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • 3-point major adverse cardiovascular events (MACE) [60 months]
  • Hospitalization for heart failure (specific, based on primary inpatient diagnosis code) [60 months]
  • Hospitalization for heart failure (broad, based on any inpatient diagnosis code) [60 months]
  • Modified MACE [60 months]
  • Composite of MI or stroke hospital admission for heart failure [60 months]
  • All-cause mortality [60 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.